Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Tranylcypromine Sulfate | |
| Synonyms |
|
|
| Definitions |
The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C61980 |
|
| CAS_Registry |
13492-01-8
|
|
| CHEBI_ID |
CHEBI:9653
|
|
| Chemical_Formula |
2C9H11N.H2SO4
|
|
| code |
C61980
|
|
| Contributing_Source |
FDA
|
|
| definition |
The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.
|
|
| FDA_UNII_Code |
7ZAT6ES870
|
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Tranylcypromine Sulfate
|
|
| Legacy Concept Name |
Tranylcypromine_Sulfate
|
|
| Maps_To |
Tranylcypromine Sulfate
|
|
| NCI_Drug_Dictionary_ID |
765903
|
|
| PDQ_Closed_Trial_Search_ID |
765903
|
|
| PDQ_Open_Trial_Search_ID |
765903
|
|
| Preferred_Name |
Tranylcypromine Sulfate
|
|
| prefixIRI |
NCIT:C61980
|
|
| prefLabel |
Tranylcypromine Sulfate
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0304369
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |